LEVEL OF GROWTH FACTOR IN TARGETED CHEMOEMBOLIZATION OF RENAL CELL CARCINOMA
- Autores: Maksimov A.V1, Martov A.G2,3,4, Tapyev E.V1
-
Afiliações:
- Republican Hospital №1 National Medical Center
- Federal Medical and Biological Center named after A.I. Burnazyan FMBA RF
- Lomonosov Moscow State University
- City clinical hospital named after D.D. Pletnev of the Health Department c. Moscow
- Edição: Nº 3 (2022)
- Páginas: 103-107
- Seção: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/277233
- DOI: https://doi.org/10.18565/urology.2022.3.103-107
- ID: 277233
Citar
Texto integral
![Acesso aberto](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_open.png)
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_unlock.png)
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Resumo
Palavras-chave
Texto integral
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Sobre autores
A. Maksimov
Republican Hospital №1 National Medical Center
Email: maximov_alex1971@mail.ru
Head of the Department of Urology Yakutsk, Russia
A. Martov
Federal Medical and Biological Center named after A.I. Burnazyan FMBA RF; Lomonosov Moscow State University; City clinical hospital named after D.D. Pletnev of the Health Department c. Moscow
Email: martovalex@mail.ru
corresponding member of RAS, Ph.D., MD, professor, head of the Department of Urology and Andrology of Federal Medical and Biological Center named after A.I. Burnazyan FMBA RF, leading researcher of the Department of Urology and Andrology of Medical Scientific and Educational Center of Lomonosov Moscow State University, Head of the Urology Department of City clinical hospital named after D.D. Pletnev of the Health Department c. Moscow” Moscow, Russia
E. Tapyev
Republican Hospital №1 National Medical Centerphysician of medical and genetic center of GAU RS Yakutsk, Russia
Bibliografia
- Велиев Е.И., Богданов А.Б. Особенности метастазирования рака почки, хирургическое лечение рецидивов и метастазов. Практическая онкология. 2005;3(6):167-171.
- Чиссов В. П., Старинский В. В., Петрова Г. В. Злокачественные новообразования в России в 2007 г. М.: ФГБУ «МНИОИ им. П.А. Герцена». 2009:6-8.
- Motzer R.J., Bukowski R.M., Figlin R.A. et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2008;113(7):1 552-1558. doi: 10.1002/cncr.23776.
- Алексеев Б.Я., Калпинский А.С. Сорафениб в последовательной терапии метастатического рака почки. Медицинский совет 2013;(5- 6):86-90.
- Zarrin B., Zarifi F., Vaseghi G., Javanmard S.H. Acquired tumor resistance to antiangiogenic therapy: Mechanisms at a glance. J. Res. Med. Sci. 2017;22:117.
- Матвеев В.Б., Волкова М.И. Рак почки. Русский медицинский журнал 2007;(14):1094-1099.
- Nerich V., Hugues M., Paillard M.J. et al. Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma. Onco Targets Ther. 2014;7:365-374. doi: 10.2147/OTT.S56370
- Piccirillo J.F., Tierney R.M., Costas I. et al. Prognostic Importance of Comorbidity in a Hospital-Based Cancer Registry. JAMA 2004;291(20):2441-2447. doi: 10.1001/jama.291.20.2441. PMID: 15161894.
- Чубенко В.А. Осложнения таргетной терапии. Практическая онкология 2010;11(3):192-202).
- Максимов А.В. Неустроев П.А. Способ баллонной химиоэмболизации и резекции злокачественных опухолей паренхиматозных органов. Патент РФ на изобретение № 2711549. Государственный реестр изобретений Российской Федерации. 17.01.2020.
Arquivos suplementares
![](/img/style/loading.gif)